PAP
COGT icon

Persistent Asset Partners’s Cogent Biosciences COGT Stock Holding History

Persistent Asset Partners’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-59,797
Closed -$223K – 256
2025
Q2 		$223K Buy
59,797
+59,318
+12,384% +$329K 0.17% 109
2025
Q1 		$72K Buy
+479
New +$3.76K 0.06% 122

Other funds holding COGT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Persistent Asset Partners's COGT Position: Q1 2026 in Review

Persistent Asset Partners increased its Cogent Biosciences (COGT) stake by 95% in Q1 2026, buying an estimated $1.66M and bringing the position to 92,516 shares worth $3.56M. The position accounts for 1.33% of the portfolio, ranked #14.

Persistent Asset Partners first reported a position in COGT in Q4 2024 and has held it in 6 quarters since. 305 funds tracked by Wall St. Rank hold COGT as of Q1 2026.

  • Persistent Asset Partners held 92,516 shares of Cogent Biosciences worth $3.56M as of Q1 2026.
  • Persistent Asset Partners bought 45,017 Cogent Biosciences shares in Q1 2026, an estimated $1.66M.
  • Cogent Biosciences made up 1.33% of Persistent Asset Partners's portfolio in Q1 2026, its #14 holding.
  • Persistent Asset Partners first reported a position in Cogent Biosciences in Q4 2024 and has held it in 6 quarters since.
  • 305 funds tracked by Wall St. Rank held Cogent Biosciences as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.